JP2011528352A - 創傷の治癒 - Google Patents

創傷の治癒 Download PDF

Info

Publication number
JP2011528352A
JP2011528352A JP2011518733A JP2011518733A JP2011528352A JP 2011528352 A JP2011528352 A JP 2011528352A JP 2011518733 A JP2011518733 A JP 2011518733A JP 2011518733 A JP2011518733 A JP 2011518733A JP 2011528352 A JP2011528352 A JP 2011528352A
Authority
JP
Japan
Prior art keywords
human
secreted protein
purified
isolated
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011518733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528352A5 (enExample
Inventor
サノス，クリストファー
ビンツ，ブライアンナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2011528352A publication Critical patent/JP2011528352A/ja
Publication of JP2011528352A5 publication Critical patent/JP2011528352A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/733—Alginic acid; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2011518733A 2008-07-15 2009-07-15 創傷の治癒 Pending JP2011528352A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13502608P 2008-07-15 2008-07-15
US61/135,026 2008-07-15
PCT/US2009/004129 WO2010008573A2 (en) 2008-07-15 2009-07-15 Wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016002681A Division JP6309033B2 (ja) 2008-07-15 2016-01-08 創傷の治癒

Publications (2)

Publication Number Publication Date
JP2011528352A true JP2011528352A (ja) 2011-11-17
JP2011528352A5 JP2011528352A5 (enExample) 2012-09-13

Family

ID=41550919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011518733A Pending JP2011528352A (ja) 2008-07-15 2009-07-15 創傷の治癒
JP2016002681A Active JP6309033B2 (ja) 2008-07-15 2016-01-08 創傷の治癒

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016002681A Active JP6309033B2 (ja) 2008-07-15 2016-01-08 創傷の治癒

Country Status (6)

Country Link
US (2) US20110177025A1 (enExample)
EP (1) EP2318034B1 (enExample)
JP (2) JP2011528352A (enExample)
AU (3) AU2009271598A1 (enExample)
NZ (1) NZ591037A (enExample)
WO (1) WO2010008573A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013118877A1 (ja) * 2012-02-10 2015-05-11 株式会社ジャパニック 非ヒト幹細胞の培養上清を原材料とする化粧品又は皮膚再生促進剤、及びタンパク質のイオン導入方法
JP2020033370A (ja) * 2017-12-26 2020-03-05 大太朗 福岡 増毛、頭皮若しくは皮膚の改質、創傷治癒、骨形成促進、または毛髪の改質に用いるための医薬組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010091253A1 (en) * 2009-02-06 2010-08-12 Women & Infants' Hospital Of Rhode Island Compositions, formulations and methods of treating preeclampsia-type disorders of pregnancy
WO2012126369A1 (zh) * 2011-03-22 2012-09-27 北京三诺佳邑生物技术有限责任公司 核苷酸、包括其的重组载体、细胞、组合物及它们的应用
US20130123647A1 (en) 2011-05-03 2013-05-16 The Research Foundation Of State University Of New York Methods Useful in Optimizing the Treatment of Neuropathies and Targeting Tissues with Cosmetic Botulinum Injections
EP2687224A1 (en) * 2012-07-19 2014-01-22 Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH Medicament for wound treatment
US20140088402A1 (en) 2012-09-25 2014-03-27 Innovative Therapies, Inc. Wound measurement on smart phones
CN106906180A (zh) 2016-12-28 2017-06-30 里程 一种具有生物活化作用的复合添加剂及其制备方法和用途
CN113274538B (zh) * 2021-05-28 2022-09-06 中国科学院过程工程研究所 一种具有创面主动修复功能的bFGF缓释纳米敷料及其制备方法和应用
CN114381421B (zh) * 2022-02-09 2023-08-15 河北医科大学 溶菌酶诱导的小鼠血管平滑肌细胞炎症模型及其建立方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021A (en) * 1845-05-01 Isaac l
US8011A (en) * 1851-04-01 Improvement in blasti ng rocks
WO2000066188A2 (en) * 1999-04-30 2000-11-09 Diatranz Limited Xenotransplant for cns therapy
JP2005524633A (ja) * 2002-02-08 2005-08-18 ユニバーシティ オブ サウス フロリダ 増殖した細胞系およびその使用方法
WO2006112734A1 (en) * 2005-04-18 2006-10-26 Neurotrophincell Pty Limited Choroid plexus preparation and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020127594A1 (en) * 2000-06-22 2002-09-12 Gearing David P. Don-1 gene and polypeptides and uses therefor
US20050265977A1 (en) * 1999-04-30 2005-12-01 Elliott Robert B Xenotransplant for CNS therapy
US20040213768A1 (en) * 1999-04-30 2004-10-28 Elliott Robert Bartlett Preparation for biotransplantation and xenotransplantion and uses thereof
US20040009915A1 (en) * 2002-03-06 2004-01-15 Han Chang Polynucleotides encoding a novel intracellular chloride channel-related polypeptide
NZ540597A (en) * 2005-06-08 2007-02-23 Neurotrophincell Pty Ltd A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
WO2007028053A2 (en) * 2005-09-02 2007-03-08 X-Cell Medical Incorporated Methods of treating and preventing cardiac disorders
CA2580907A1 (en) * 2006-11-21 2008-05-21 The Bionic Ear Institute Choroid plexus cell implantation to prevent and/or treat hearing loss
ES2324192B1 (es) * 2008-01-30 2010-06-17 PUIG BEAUTY & FASHION GROUP, S.L. Derivados peptidicos utiles en el tratamiento, cuidado o limpieza de la piel, mucosa, cuero cabelludo o uñas.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021A (en) * 1845-05-01 Isaac l
US8011A (en) * 1851-04-01 Improvement in blasti ng rocks
WO2000066188A2 (en) * 1999-04-30 2000-11-09 Diatranz Limited Xenotransplant for cns therapy
JP2005524633A (ja) * 2002-02-08 2005-08-18 ユニバーシティ オブ サウス フロリダ 増殖した細胞系およびその使用方法
WO2006112734A1 (en) * 2005-04-18 2006-10-26 Neurotrophincell Pty Limited Choroid plexus preparation and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013051640; Ａｒｔｉｆ　Ｏｒｇａｎｓ．，　Ｖｏｌ．２８　Ｎｏ．１　（２００４）　ｐ．１３-２１． *
JPN6013051641; Ｏｒａｌ　Ｓｕｒｇ　Ｏｒａｌ　Ｍｅｄ　Ｏｒａｌ　Ｐａｔｈｏｌ　Ｏｒａｌ　Ｒａｄｉｏｌ　Ｅｎｄｏｄ．，　Ｖｏｌ．１０１　Ｎｏ．３　（２００６）　ｐ．ｅ５６-６０． *
JPN6013051642; Ｊ　Ｏｒｔｈｏｐ　Ｔｒａｕｍａ．，　Ｖｏｌ．２２　Ｎｏ．６　（２００８　Ｊｕｌｙ）　ｐ．４３３-８． *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2013118877A1 (ja) * 2012-02-10 2015-05-11 株式会社ジャパニック 非ヒト幹細胞の培養上清を原材料とする化粧品又は皮膚再生促進剤、及びタンパク質のイオン導入方法
JP2020033370A (ja) * 2017-12-26 2020-03-05 大太朗 福岡 増毛、頭皮若しくは皮膚の改質、創傷治癒、骨形成促進、または毛髪の改質に用いるための医薬組成物
JP2020128399A (ja) * 2017-12-26 2020-08-27 大太朗 福岡 増毛、頭皮若しくは皮膚の改質、創傷治癒、骨形成促進、または毛髪の改質に用いるための医薬組成物
US11413321B2 (en) 2017-12-26 2022-08-16 Hirotaro FUKUOKA Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair
US12343369B2 (en) 2017-12-26 2025-07-01 Hirotaro FUKUOKA Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair

Also Published As

Publication number Publication date
US20180008644A1 (en) 2018-01-11
WO2010008573A3 (en) 2010-05-27
AU2018201925B2 (en) 2020-05-28
EP2318034A2 (en) 2011-05-11
AU2018201925C1 (en) 2020-09-17
EP2318034A4 (en) 2012-08-22
WO2010008573A2 (en) 2010-01-21
AU2009271598A1 (en) 2010-01-21
JP2016121158A (ja) 2016-07-07
NZ591037A (en) 2013-02-22
AU2018201925A1 (en) 2018-04-12
EP2318034B1 (en) 2017-03-22
JP6309033B2 (ja) 2018-04-11
AU2016202913A1 (en) 2016-05-26
US20110177025A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
JP6309033B2 (ja) 創傷の治癒
CN101815531B (zh) 含细胞因子溶液的新组合物
JP4653887B2 (ja) 創傷治療用のミクロスフェアを含む組成物
EP2139497A2 (en) Methods for treating nervous system injury and disease
JPH05506673A (ja) 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
TWI857807B (zh) 含有粒線體之組合物及其用於作為皮膚纖維母細胞活性促進劑之用途
CN102781463A (zh) 用于皮肤再生的方法和组合物
US20180207095A1 (en) Cell tissue gel containing collagen and hyaluronan
JP4102437B2 (ja) アクチビンおよびインヒビン刺激因子を含有する医薬組成物
KR20210093252A (ko) 연골세포 증식을 조절하고 연골 기질 생산을 증가시키기 위한 조성물 및 방법
US20090232784A1 (en) Endothelial predecessor cell seeded wound healing scaffold
KR101033135B1 (ko) 상처 치유용 조성물 및 그의 용도
CN105263507A (zh) 使用sdf-1减轻瘢痕形成
KR20130052441A (ko) 재조합 인간 골형성 단백질과 트위스트 전사인자를 활성성분으로 함유하는 피부조직 재생용 조성물 및 키트
US11890322B2 (en) Methods for promoting wound healing and hair growth comprising GDNF administration
KR20130109850A (ko) 재조합 인간 골형성 단백질을 활성성분으로 함유하는 피부조직 재생용 키트
CN120053685A (zh) 载kgn的纳米囊泡、溶解性微针及其制备方法与应用
EP2040754B1 (fr) Utilisation de fractions cellulaires du tissu adipeux pour la regeneration tissulaire post irradiation
WO2007145889A1 (en) Methods of treating spinal cord injury and minimizing scarring
Hrynyk Enhanced burn wound healing through controlled and sustained delivery of bioactive insulin from alginate sponge dressings
AU2023420042A1 (en) Composition and method for wound healing and repair of damaged nerves
CN1579539A (zh) 胸腺素β15促进伤口愈合及血管生成
CN119215023A (zh) 一种通过激活成纤维细胞进行创面修复的方法
JP2023552515A (ja) 創傷を治療するための組成物および方法
McCauley Mesenchymal Stem Cells, TGF-B3, and an Albumin Scaffold to Promote Full Thickness Wound Healing

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150908